ライフサイエンスコーパス: HLA-matched

1 lay a role in clinical BMT rejection that is HLA matched.

2 antation period was 79% (95% CI 74-85) after HLA matched, 76% (71-81) after one allele mismatched, 70

3 -cell grafts for adults in the absence of an HLA-matched adult donor.

4 ematopoietic stem cells for patients without HLA-matched adult donors.

5 s (PBPCs) or bone marrow, especially when an HLA-matched adult unrelated donor is not available.

6 ssigned to the remaining patients undergoing HLA-matched allo HCT (validation cohort; n = 577) as wel

7 portunity to optimize GvHD prophylaxis after HLA-matched alloBMT and increase the use of HLA-mismatch

8 prophylaxis of acute and chronic GvHD after HLA-matched alloBMT.

9 ve burden experienced by patients undergoing HLA-matched alloBMT.

10 ctivity of sequential infusions of partially HLA-matched allogeneic blood mononuclear cells (obtained

11 (GVHD) and graft-versus-leukemia effects in HLA-matched allogeneic blood or marrow transplantation (

12 nt were given one to six infusions of partly HLA-matched allogeneic EBV-specific cytotoxic T lymphocy

13 61 patients were enrolled, 42 were HLA matched and 19 were haploidentical.

14 Tolerance to HLA matched and mismatched living donor kidney transplan

15 prognostic of outcome in patients undergoing HLA-matched and -mismatched allo HCT for MDS.

16 T leaders were established in 17 100 (50.3%) HLA-matched and 1457 (4.3%) single HLA-B-mismatched tran

17 we genotyped donors and recipients from 209 HLA-matched and 239 mismatched T-replete URD transplanta

18 ukemia (CML), we investigated the ability of HLA-matched and mismatched CD56(+) cells to inhibit gran

19 IS drugs has been achieved in recipients of HLA-matched and mismatched living donor kidney transplan

20 dence interval 0.48-0.86; P = .003) for both HLA-matched and mismatched transplants.

21 These data support the use of HLA-matched and one- or two-antigen HLA-mismatched umbil

22 13% from HLA-mismatched relatives, 12% from HLA-matched, and 41% from HLA-mismatched unrelated donor

23 ntation of antigen to these T-cell clones by HLA-matched antigen-presenting cells exposed to the inta

24 transplants in these patients are routinely HLA matched, any immunization responsible for increased

25 unction, and an unrelated adult marrow donor HLA matched at the allele level for HLA A, B, C, and DRB

26 evaluate closely histocompatibility antigen (HLA)-matched banked antigen-specific T cells so that T-c

27 tineoplastic effects of irradiated partially HLA-matched blood mononuclear cells obtained from relati

28 Because the optimal timing of HLA-matched BMT for MDS is unknown, we constructed a Mar

29 yields similar survivals to those seen with HLA-matched BMT.

30 titutional study of human leukocyte antigen (HLA) -matched bone marrow transplantation would provide

31 When successful, human leukocyte antigen (HLA)-matched bone marrow transplantation with reduced-in

32 that had one HLA mismatch (83 patients), and HLA-matched bone marrow (367 patients).

33 lable to most patients due to the lack of an HLA-matched bone marrow donor.

34 r many nonmalignant hematological disorders, HLA-matched bone marrow transplantation (BMT) is curativ

35 Thus CTL were advantageous when functionally HLA matched but for certain tumor types complete respons

36 GVHD after prophylactic CD4+ DLI after 10/10-HLA-matched, but HLA-DPB1-mismatched TCD-alloSCT.

37 y (TRM), and overall mortality compared with HLA-matched cases (8/8).

38 received an allogeneic HCT with four of six HLA-matched CCR5 Delta32 homozygous cord blood cells (St

39 is considered a future clinical strategy for HLA-matched cell transplantation to reduce immunological

40 sorbent spot assays with pools of predicted, HLA-matched, class I binding peptides covering the entir

41 lity in a training subset (n = 1,151) of the HLA-matched cohort.

42 sed tetramer(+) CD4(+) T cells compared with HLA-matched control subjects without diabetes.

43 some people with recent-onset T1D but not in HLA-matched control subjects.

44 -A*24(+) recent-onset patients compared with HLA-matched control subjects.

45 91%) compared with children receiving a well HLA-matched DBD kidney transplant (83%, 95% CI, 80-86%,

46 stify preferentially waiting for an improved HLA-matched DBD kidney when a poorer HLA-matched LD kidn

47 mes are not inferior when compared with well HLA-matched DBD renal transplants.

48 For patients without an available HLA matched donor, the use of 2 partially HLA-matched UC

49 ihoods of finding a human leukocyte antigen (HLA)-matched donor for patients of various racial/ethnic

50 easible alternative for patients who lack an HLA-matched donor and can now be applied to treat patien

51 ion is limited by availability of a suitable HLA-matched donor and lack of awareness of the benefits

52 onmyeloablative regimen followed by combined HLA-matched donor bone marrow and renal allotransplantat

53 stem cell transplantation (AlloSCT) utilizes HLA-matched donor bone marrow or peripheral blood stem c

54 ers can improve the likelihood of finding an HLA-matched donor, but will still leave significant numb

55 For patients without a suitable related HLA-matched donor, unrelated-donor registries of adult v

56 ed a HSCT at any age from an unrelated 10/10 HLA-matched donor, with a myeloablative conditioning reg

57 y and hematopoietic-cell transplants from an HLA-matched donor.

58 e suitable alternatives for patients with no HLA-matched donor.

59 er-small bowel transplantation from a 1-of-6 HLA-matched donor.

60 in each of the eight HLA-mismatched and one HLA-matched donor/recipient pairs.

61 31 patients had HLA matched donors who were related and 18 had donors wh

62 uable strategy for identifying more suitably HLA-matched donors and has the potential for alleviating

63 ation can cure sickle cell disease; however, HLA-matched donors are difficult to find, and the toxici

64 the main post-transplantation challenge when HLA-matched donors are unavailable.

65 he use of banked VSTs derived from partially HLA-matched donors has shown efficacy in multicenter set

66 atopoietic progenitor cells and T cells from HLA-matched donors in a tolerance induction protocol.

67 ents should receive granulocytes from either HLA-matched donors or donors selected by leukoagglutinat

68 HLA typing, should be performed to identify HLA-matched donors with B KIR haplotypes.

69 Fifty-seven HLA-matched donors, 12 HLA-mismatched donors, and 1 CD3(

70 The best outcomes have been achieved with HLA-matched donors, but when a matched donor is not avai

71 n successfully performed in patients with no HLA-matched donors, leukemia caused by vector-mediated i

72 a show that the outcome of HSCT for SCN from HLA-matched donors, performed in recent years, in patien

73 Better HLA-matched donors, use of bone marrow, and transplantat

74 GVHD after bone marrow transplantation from HLA-matched donors.

75 uld no longer be restricted to patients with HLA-matched donors.

76 to children with major SCD complications and HLA-matched donors.

77 nrelated adult donor (MMUD, n = 52) or 4-6/6 HLA matched dUCB (n = 128) graft after myeloablative con

78 minished cytotoxicity against allogeneic and HLA-matched EBV-B cells.

79 Ls produced infectious virus when exposed to HLA-matched EBV-expressing targets, but not on exposure

80 of testing a total of 199 embryos, 45 (23%) HLA-matched embryos were selected, of which 28 were tran

81 We investigated the use of non-HLA-matched ex-vivo expanded cord blood progenitor cells

82 t of the study was safety of infusion of non-HLA-matched expanded cord blood progenitor cells after a

83 not have a suitable human leukocyte antigen (HLA)-matched family donor, unrelated donor registries of

84 tients with severe PNH underwent HCT from an HLA-matched family donor after conditioning with cycloph

85 If HLA-matched sibling donor/HLA-matched family donor HSCT or HSC-GT are not availabl

86 If an HLA-matched sibling donor or HLA-matched family donor is available, allogeneic hemato

87 bone-marrow transplantation is successful if HLA-matched family donors are available, but HLA-mismatc

88 ter randomisation, patients either receive a HLA-matched graft (experimental intervention) or a rando

89 3; P=0.001); the risk was also higher in the HLA-matched group than in the cord-blood group but not s

90 I, 0.76 to 2.46; P=0.30; hazard ratio in the HLA-matched group, 0.78; 95% CI, 0.48 to 1.28; P=0.33).

91 I, 0.51 to 3.25; P=0.60; hazard ratio in the HLA-matched group, 1.30; 95% CI, 0.65 to 2.58; P=0.46).

92 I, 1.22 to 7.38; P=0.02; hazard ratio in the HLA-matched group, 2.92; 95% CI, 1.34 to 6.35; P=0.007).

93 nts of histocompatibility leukocyte antigen (HLA)-matched, HA-1-mismatched renal transplants, one of

94 leukaemia who received a myeloablative 10/10 HLA-matched haematopoietic stem-cell transplantation (HS

95 mic relapse, but capturing alloreactivity in HLA-matched HCT has been elusive.

96 In clinical settings, HLA-matched HCT is preferred to facilitate engraftment a

97 1-mediated inhibition in donor selection for HLA-matched HCT may achieve superior graft versus leukem

98 125 cord blood, 125 HLA-mismatched, and 154 HLA-matched HCTs, detection of multiple viruses was comm

99 measured by an IFN-gamma T cell response in HLA-matched HCV-infected individuals.

100 ween Type 1 diabetes patients and age/gender/HLA-matched healthy adults.

101 ng in 5 singleton pregnancies and birth of 5 HLA-matched healthy children.

102 When considering HLA-matched hematopoietic cell transplantation (HCT), si

103 These results demonstrate that a majority of HLA-matched hematopoietic cell transplantations involve

104 panded donor natural killer (NK) cells after HLA-matched hematopoietic stem cell transplantation (HSC

105 de, achieving results comparable to those of HLA-matched hematopoietic stem cell transplantation.

106 r did not persist in the plasma of their non-HLA-matched HIV-1-infected infants.

107 Studies in HLA-matched HSCT, however, have also demonstrated improv

108 confirm that NK alloreactivity can occur in HLA-matched HSCT, where tolerance to self is either acqu

109 eneic HSCT and was suggested not to occur in HLA-matched HSCT.

110 ng memory CD8(+) T cell clones, we looked in HLA-matched IM patients and found such reactivities but

111 ells in tonsillar mononuclear cells (MNC) of HLA-matched individuals.

112 8+ T cells in tonsillar mononuclear cells of HLA-matched individuals.

113 was superior for children receiving a poorly HLA-matched LD kidney transplant (88%, 95% confidence in

114 mproved HLA-matched DBD kidney when a poorer HLA-matched LD kidney transplant is available.

115 In children, poorly HLA-matched LD renal transplant outcomes are not inferio

116 o cytotoxic and can control the outgrowth of HLA-matched lymphoma cells in cocultivation assays.

117 and secreted interferon-gamma in response to HLA-matched melanocytes and cultured lymphangioleiomyoma

118 cific T cells were cytotoxic toward gp100(+) HLA-matched melanoma targets, but not HLA-mismatched mel

119 In HLA-matched mixed leukocyte reactions, we also observed

120 and the risk of chronic GVHD associated with HLA-matched mobilized blood cell grafts can be substanti

121 lood were transplanted with grafts that were HLA-matched (n=35) or HLA-mismatched for one (n=201) or

122 ng couples with a realistic option of having HLA-matched offspring to serve as potential donors of st

123 Transfusion avoidance or the use of HLA matched or selected blood may reduce this risk and i

124 2, were cocultured with responder cells from HLA-matched or -mismatched donors.

125 These CD4+ T cells recognize NY-ESO-1(+), HLA-matched or autologous melanoma cell lines, as well a

126 st candidates for HSCT will have a suitable (HLA-matched or minimally mismatched) adult donor.

127 npermissive HLA-DPB1 mismatches in otherwise HLA-matched pairs is indicated.

128 ne +/- TBI), and 8 of 8 (n = 313) and 7 of 8 HLA-matched PBPCs (n = 111).

129 od donors were tested for reactivity against HLA-matched peptides by using gamma interferon enzyme-li

130 ymocyte globulin, followed by an infusion of HLA-matched peripheral-blood mononuclear cells from rela

131 sfusions because of alloimmunization require HLA-matched platelets, which is only possible if a large

132 ailability and selection of crossmatched and HLA-matched platelets.

133 l strategy for prioritizing among comparably HLA-matched potential donors has not been established.

134 KIR genotyping of several best HLA-matched potential unrelated donors should substantia

135 nd confers specific cytotoxicity against KIR/HLA-matched PSCA-positive tumor cells, which was further

136 Rapid disease progression is observed in HLA-matched recipients to whom mutated virus is transmit

137 antation (HCT) from human leukocyte antigen (HLA) matched related donor (MRD) and matched unrelated d

138 splantation with an human leukocyte antigen (HLA)-matched related donor (MRD, n = 204), HLA allele-ma

139 to lack of a fully human leukocyte antigen (HLA)-matched related donor.

140 alignancies; 78 had human leukocyte antigen (HLA)-matched related donors and 39 had HLA-matched unrel

141 -agent GVHD prophylaxis after myeloablative, HLA-matched related (MRD), or HLA-matched unrelated (MUD

142 We carried out HLA-matched related (n = 16) and unrelated (n = 17) hema

143 ral blood stem-cell (n = 18) transplant from HLA-matched related (n = 18) or unrelated (n = 2), or 1

144 syngeneic (n = 2) HCT and were treated with HLA-matched related (n = 62) or unrelated (n = 85) graft

145 Our study indicates that HLA-matched related BMT is an effective treatment for pe

146 here is considerable variation in the use of HLA-matched related bone marrow transplantation (BMT) fo

147 topoietic cell transplantation (HCT) have an HLA-matched related donor (MRD) available to them.

148 In multivariate analysis, HLA-matched related donor and prophylaxis with cyclospor

149 oablative and 73 myeloablative recipients of HLA-matched related donor HCT, using the National Cancer

150 Younger patients and recipients of HLA-matched related donor transplantations who have cyto

151 nsplantation and had an available 8/8 or 7/8 HLA-matched related donor.

152 an allogeneic stem cell transplant from her HLA-matched related donor.

153 In transplantations from HLA-matched related donors (n = 82), younger patients (<

154 ogic malignancies who were given grafts from HLA-matched related donors following conditioning with 2

155 gnancies undergoing TCD transplantation from HLA-matched related donors without the use of ATG.

156 T) to bone marrow transplantation (BMT) from HLA-matched related donors, we found no statistically si

157 ed 17, 14 from HLA-haploidentical and 3 from HLA-matched related donors.

158 osuppression after nonmyeloablative HCT with HLA-matched related grafts.

159 I haplotype also occurs in AML relapse after HLA-matched related HSCT.

160 against graft-versus-host disease (GVHD) in HLA-matched related or unrelated allogeneic hematopoieti

161 ts given hematopoietic cell transplants from HLA-matched related or unrelated donors after conditioni

162 Patients with HLA-matched related or unrelated donors had similar surv

163 e age of 10 years, in recent years, and from HLA-matched related or unrelated donors were associated

164 = 135) or RIC (n = 137) followed by HCT from HLA-matched related or unrelated donors.

165 ng factor (G-CSF)-mobilized blood cells from HLA-matched related or unrelated donors.

166 orts of patients having the same donor type (HLA-matched related, unrelated, or both) reported in the

167 21 HLA-matched related-donor and 35 HLA-matched unrelated-d

168 e marrow or peripheral blood stem cells from HLA-matched related-donors or HLA-9/10 or HLA-10/10 matc

169 hylaxis after myeloablative conditioning and HLA-matched-related or -unrelated T-cell-replete allogra

170 donor cells/kg); the donor was the patient's HLA-matched, rheumatoid factor-negative sister.

171 survival similar to those of contemporaneous HLA-matched RIC HSCT at our institution.

172 reatment-related mortality (P < .001) in the HLA-matched set and relapse (P < .001) in the HLA-mismat

173 riteria as are currently used for those with HLA matched sibling donors.

174 Human leukocyte antigen (HLA)-matched sibling donor (MSD) HSCT remains the gold s

175 -five patients with human leukocyte antigen (HLA)-matched sibling donors underwent T-cell-depleted al

176 ly) obtained from a human leukocyte antigen (HLA)-matched sibling.

177 There were 811 HLA-matched sibling (61%) and 522 (39%) unrelated donor

178 We compared these results with HLA-matched sibling (matched sibling donors [MSDs]) BMT

179 d unrelated donor (MUD) rather than an older HLA-matched sibling (MSD).

180 Donors were HLA-matched sibling (n = 1), HLA-matched unrelated (n =

181 onstrated superior 5-year outcome after auto/HLA-matched sibling allo HSCT compared with tandem auto

182 abilities of survival were 62% and 62% after HLA-matched sibling and 42% and 39% after alternative do

183 of death, accounting for 50% of deaths after HLA-matched sibling and 43% of deaths after alternative

184 cidence of neutrophil recovery was 66% after HLA-matched sibling and 61% after alternative donor tran

185 eukemia-free survival were 49% and 54% after HLA-matched sibling and unrelated donor transplantation

186 sults suggest that allogeneic HSCT from both HLA-matched sibling and unrelated donors can induce dura

187 ed over time, particularly for patients with HLA-matched sibling and unrelated donors.

188 ars of age with class 3 thalassemia received HLA-matched sibling BMT following either the original pr

189 Allogeneic bone marrow transplant from an HLA-matched sibling can halt disease progression but is

190 Long-term survival was higher after HLA-matched sibling compared to alternative donor transp

191 EFS after HLA-matched sibling donor (MSD) and 6/6 matched unrelate

192 utcome of patients who received conventional HLA-matched sibling donor (SIB) and HLA-matched unrelate

193 hat the majority of children with a suitable HLA-matched sibling donor can expect a cure from this ap

194 rce, disease risk, age, and transplant year, HLA-matched sibling donor marrow resulted in the best GR

195 Patients age 13 years or older with an HLA-matched sibling donor or age 12 years or younger wit

196 If an HLA-matched sibling donor or HLA-matched family donor is

197 n the best GRFS (51%, 95% CI 46-66), whereas HLA-matched sibling donor peripheral blood stem cells we

198 Among HLA-matched sibling donor transplantation recipients, th

199 These data support HLA-matched sibling donor transplantation using a TBI-co

200 rt, patients age 12 years or younger with an HLA-matched sibling donor were at the lowest risk with a

201 s hematopoietic stem cell transplant from an HLA-matched sibling donor, although <25% of patients hav

202 c hematopoietic cell transplant will have an HLA-matched sibling donor.

203 roup) on the basis of the availability of an HLA-matched sibling donor.

204 unfavorable cytogenetics who lack a suitable HLA-matched sibling donor.

205 at age 12 years or younger and those with an HLA-matched sibling donor.

206 If HLA-matched sibling donor/HLA-matched family donor HSCT

207 myeloma and end-stage renal disease with an HLA-matched sibling donor; the second for patients with

208 ts in first CR (28% versus 3%, P =.008), and HLA-matched sibling donors (81% versus 40%, P =.001).

209 those of transplantation using conventional HLA-matched sibling donors (MRDs) and HLA-matched unrela

210 Cy) is increasingly used in patients lacking HLA-matched sibling donors (MSD).

211 and the remainder received bone marrow from HLA-matched sibling donors for predominantly high-risk h

212 Sixty-seven patients with HLA-matched sibling donors received fractionated total b

213 ted allogeneic SCT, and 137 patients without HLA-matched sibling donors underwent autologous SCT.

214 Allografts from HLA-matched sibling donors were mobilized and collected

215 (91%) were included (558 [61%] patients had HLA-matched sibling donors, 137 [15%] haploidentical rel

216 Most likely to benefit are patients who have HLA-matched sibling donors, are in remission, and have g

217 LA-A, HLA-B, HLA-C, and HLA-DRB1), including HLA-matched sibling donors, haploidentical related donor

218 no difference was seen in patients receiving HLA-matched sibling grafts.

219 Thus, in HLA-matched sibling HSCT for myeloid leukemia, patients

220 determined in 220 donor-recipient pairs from HLA-matched sibling HSCTs performed for myeloid (n = 112

221 GVH-mismatched unrelated recipients than in HLA-matched sibling recipients.

222 ents enrolled in chemotherapy trials and 186 HLA-matched sibling transplants, treated between 1991 an

223 received T-cell-replete bone marrow from an HLA-matched sibling.

224 living donor kidney transplants (LDKTx) from HLA matched siblings (termed HLA-identical (HLA-ID)) to

225 s were primarily peripheral blood (77%) from HLA-matched siblings (40%) or well-matched unrelated don

226 hematopoietic stem cells were obtained from HLA-matched siblings (n = 4) and unrelated donors (n = 4

227 CD4(+) T cells in 32 donor SCTs infused into HLA-matched siblings and examined GVHD incidence in resp

228 The introduction of donors other than HLA-matched siblings has been a pivotal change in stem c

229 expansion of potent mHA-specific Tregs from HLA-matched siblings in sufficient numbers for applicati

230 imulated by dendritic cells (DCs) from their HLA-matched siblings in the presence of interleukin 2, i

231 four percent of transplants used grafts from HLA-matched siblings, 13% from HLA-mismatched relatives,

232 onths (IQR 18-60) after transplantation from HLA-matched siblings, 25 months (12-48) after transplant

233 s to safely undergo BMT from RDs who are not HLA-matched siblings, with transplant outcomes similar t

234 ing factor (G-CSF), which were obtained from HLA-matched siblings.

235 After HLA-matched stem cell transplantation, KIR repertoires e

236 s the time constraint of urgent provision of HLA-matched stem cells for a sick sibling.

237 contained small, undetectable, EBV-specific, HLA-matched T cell populations or perhaps they stimulate

238 -1BBL-activated NK cells (aNK-DLI) following HLA-matched, T-cell-depleted (1-2 x 10(4) T cells/kg) no

239 with the frequency of T cells reactive to an HLA-matched third party.

240 ct and transfer only those embryos that were HLA matched to affected siblings.

241 rom young donors (aged 18-32 years) who were HLA matched to recipients (P < .001).

242 recipients of units closely (7-10 to 10-10) HLA-matched to each other were more likely to demonstrat

243 I expression may be an alternative to fully HLA-matched transfusions.

244 Eighteen leukemia patients undergoing HLA-matched transplantation and their donors were analyz

245 Compared with HLA-matched transplantations, mortality was higher with

246 risk was higher among HLA-mismatched versus HLA-matched transplants (adjusted hazard ratio 1.211.431

247 acute GVHD occurred in 43% of patients given HLA-matched transplants and in 59% given partly matched

248 receptor had demonstrably higher signals in HLA-matched tumors compared with those in animals that r

249 we did not observe any responses against non-HLA-matched tumors, and no killing of any kind occurred

250 use of 2 partially human leukocyte antigen (HLA)-matched UCB units, or double UCB graft, to meet the

251 tion of 2 partially human leukocyte antigen (HLA)-matched UCB units.

252 The transplantation of 2 partially HLA-matched UCB units has been adopted as a simple appro

253 le HLA matched donor, the use of 2 partially HLA-matched UCB units is a suitable alternative.

254 Therefore, transplantation of 2 partially HLA-matched UCB units is safe, and may overcome the cell

255 e II acute GVHD in recipients of 2 partially HLA-matched UCB units, there is no adverse effect on TRM

256 ients after transplantation with 2 partially HLA-matched UCB units.

257 All patients received >/=4 antigens HLA-matched UCBT.

258 ens and possibly higher after transplants of HLA-matched umbilical cord blood.

259 r 2 (53%) partially human leukocyte antigen (HLA)-matched unit(s).

260 Compared with HLA-matched units, neutrophil recovery was lower with mi

261 ed at 1, 2, 3, 4, or 5 alleles compared with HLA-matched units.

262 out whether a male human leukocyte antigen (HLA)-matched unrelated donor (MUD, 8/8, n=2,014) might b

263 Donors were sibling (n = 75) or HLA-matched unrelated (10/10; n = 88).

264 myeloablative, HLA-matched related (MRD), or HLA-matched unrelated (MUD) donor T-cell-replete bone ma

265 Donors were HLA-matched sibling (n = 1), HLA-matched unrelated (n = 9), HLA-mismatched unrelated

266 adults with acute leukaemia when there is no HLA-matched unrelated adult donor available, and when a

267 nrelated cord-blood donor (140 patients), an HLA-matched unrelated donor (344), or an HLA-mismatched

268 en undergoing HSCT from an MRD (n = 4) or an HLA-matched unrelated donor (MUD) (n = 7); 9 children we

269 SAA patients younger than 40-50 years, with HLA-matched unrelated donor (MUD) HSCT for second line a

270 be improved with a younger allele-level 8/8 HLA-matched unrelated donor (MUD) rather than an older H

271 entional HLA-matched sibling donor (SIB) and HLA-matched unrelated donor (MUD).

272 (AML) after haploidentical (n = 192) and 8/8 HLA-matched unrelated donor (n = 1982) transplantation.

273 ) donor were similar at 81%, 66% after 10/10 HLA-matched unrelated donor (UD), and 68% after 5/6 matc

274 nts who received haploidentical (n = 185) or HLA-matched unrelated donor (URD) transplantation either

275 s that after receipt of a transplant from an HLA-matched unrelated donor and was significantly higher

276 We have carried out HLA-matched unrelated donor hematopoietic cell transplan

277 ing donor or age 12 years or younger with an HLA-matched unrelated donor were at intermediate risk (3

278 r and patients age 13 years or older with an HLA-matched unrelated donor were high risk (3-year EFS,

279 igen-matched sibling, 884 from a 7 or 8 of 8 HLA-matched unrelated donor.

280 tional HLA-matched sibling donors (MRDs) and HLA-matched unrelated donors (MUDs).

281 HLA-DPB1 alleles in patients and their 10/10 HLA-matched unrelated donors of 379 HCTs performed at ou

282 ated from HLA-genoidentical siblings or from HLA-matched unrelated donors who were identified and mat

283 37 months (23-60) after transplantation from HLA-matched unrelated donors, and 47 months (24-72) afte

284 ated donors (1.17, 0.67-2.05; p=0.58) versus HLA-matched unrelated donors, or mismatched unrelated do

285 emia, or myelodysplastic syndrome, and their HLA-matched unrelated donors, reported to the Center for

286 ogenitor cells (PBPCs) from 8 of 8 or 7 of 8 HLA-matched unrelated donors.

287 igen (HLA)-matched related donors and 39 had HLA-matched unrelated donors.

288 the clinical results of transplantation from HLA-matched unrelated donors.

289 ith AML who underwent HCT from 9/10 or 10/10 HLA-matched unrelated donors.

290 plastic syndrome who underwent myeloablative HLA-matched unrelated hematopoietic cell transplantation

291 ated with non-myeloablative conditioning and HLA-matched unrelated HSCT at the Fred Hutchinson Cancer

292 s of PTLD comparable to those reported after HLA-matched unrelated marrow myeloablative (MA) transpla

293 were KIR mismatched and 3 were matched; all HLA-matched unrelated pairs were KIR mismatched.

294 Among HLA-matched unrelated pairs, the patient's IL10/-592 gen

295 es in survival after HLA-mismatched related, HLA-matched unrelated, or mismatched unrelated donor tra

296 and 2 Gy total body irradiation followed by HLA-matched unrelated-donor HCT and postgrafting cyclosp

297 21 HLA-matched related-donor and 35 HLA-matched unrelated-donor transplants were done.

298 r non-myeloablative human leucocyte antigen (HLA)-matched, unrelated donor, allogeneic haemopoietic s

299 eive myeloablative HCT from an available 8/8-HLA matched URD.

300 Sixteen percent of units were HLA-matched with the recipient, whereas 43% and 35% had